

International Symposium on Translational Research in Viral Hepatitis

Date: 17.-19.5. 2020 (Sunday through Tuesday)

Location: Eibsee Hotel, Grainau, Germany

Capacity: 90 people



Funded by



Deutsche
Forschungsgemeinschaft
German Research Foundation

Sunday (17th of May 2020)

16:00 Welcome address

16:05- 18:00

HCV antivirals – a success story

- Ralf Bartenschlager: *The biology of HCV behind drug discovery*
- Michael Sofia (Arbutus): *The discovery and development of sofosbuvir*
- Jörg Petersen: *Clinical development and future needs*

18:00

The Perspective of Hepatitis Elimination (Jeffrey Lazarus)

18:30

Welcome reception; cheese and wine; posters

Monday (18th of May 2020)

8:30 – 10:30

HCV – vaccine development:

- Thomas Pietschmann: *HCV entry and neutralization*
 - N N: *Vector-based hepatitis C vaccines*
 - Percy Knolle: *Why T cells may not work in the liver*
- & [short talk selected from abstracts](#)

Coffee break

11:00 – 13:00

HBV – novel antiviral approaches

- Maura Dandri: *Models and biomarkers to evaluate drug efficacy*
- Klaus Klumpp: *Fast track from screening to drugs: the CpAM example*
- Amy Lee (Arbutus): *RNAi-based therapies*
- William Delaney IV (Gilead): *Novel antiviral approaches to achieve HBV cure*

13:00 – 14:00 Lunch

14:00 – 16:00

HDV – therapeutic approaches

- Stephan Urban: *Targeted therapies against HDV*
- Christoph Neumann-Haefelin: *Immune responses and therapies*
- Heiner Wedemeyer: *Clinical developments and perspectives*
- & short talk selected from abstracts

16:00-17:15 Walk around the lake and option to ride to the mountain top (Zugspitze)

17:15 – 19:00

HBV therapeutic vaccination:

- Mala Maini: *Can we break anti-HBV immune tolerance?*
- Ulrike Protzer: *Development of therapeutic hepatitis B vaccines*
- Gen evieve Inchauspe (Transgene): *Experiences from clinical development of a vector-based vaccine*
- & short talk selected from abstracts

from 20:00 Bavarian Dinner Event

Tuesday (19th of May 2020)

8:30 – 10:30

Antibody-based therapies

- Antonio Lanzavecchia: *From antibody discovery to an anti-HBV antibody*
- N N: *Antibody engineering*
- Florian Klein: *Neutralizing antibodies in antiviral treatment – clinical experience*
- & short talk selected from abstracts

Coffee break

10:45 – 13:00

T cell therapy with CARs and TCRs

- Karin Wisskirchen: *Anti-HBV CAR and TCR therapy in preclinical models*
- Antonio Bertoletti: *From the discovery of HBV-specific TCRs into the clinics*
- Dirk Busch: *Antiviral T cell therapy: from bench to bedside*
- Stan Riddell (Lyell): *T cell therapy: learning from clinical trials*

13:00 – 14:00 Lunch

14:00 – 16:00

HEV – therapeutic needs and developments

- Darius Moradpour: *Clinical challenges of HEV infection*
- Marc L utgehetmann: *HEV infection in humanized mice*
- Markus Cornberg: *Immune therapies for chronic HEV infection – a perspective?*

16:00 Summary and final comments (Dandri & Protzer)